Multiple‐dose pharmacokinetics of peginterferon alfa‐2b in patients with renal insufficiency
Authors: Gupta Samir K. , Swan Suzanne K. , Marbury Thomas , Smith William , Schwartz Sherwyn , Kolz Karen , Cutler David L. 
Published: June 2007

What is already known about this subject?

• Current therapy for hepatitis C typically consists of pegylated interferon (PEG‐IFN) alfa in combination with ribavirin.

• Pegylation of IFN alfa‐2b confers a 10‐fold increase in elimination half‐life and a 30% reduction in volume of distribution compared with non‐PEG‐IFN alfa‐2b.

• A single‐dose pharmacokinetic study conducted in patients with chronic renal dysfunction has shown that renal elimination accounts for 30% of total PEG‐IFN alfa‐2b clearance and that PEG‐IFN alfa‐2b exposure increases with severity of renal insufficiency.

What this study adds

• Because the primary mechanism of IFN clearance is catabolism in the kidney, appropriate dosing of IFN‐based therapies in patients with renal insufficiency is an important issue.

• This multiple‐dose pharmacokinetic study shows that exposure to PEG‐IFN alfa‐2b is increased in patients with renal insufficiency, suggesting that doses of the drug should be reduced by 50% in patients with severe renal insufficiency and by 25% in those with moderate insufficiency.

• PEG‐IFN alfa‐2b was well tolerated in all patient groups during the 4‐week treatment period, with similar adverse events occurring in patients with renal insufficiency and in those with normal renal function.

Aim

To evaluate the safety, tolerability and multiple‐dose pharmacokinetics of pegylated interferon (PEG‐IFN) alfa‐2b in patients with moderate or severe renal insufficiency and in those with normal renal function.

Methods

In an open‐label study, subjects with normal renal function (creatinine clearance >80 ml min−1 per 1.73 m2) and patients with moderate (30–50 ml min−1 per 1.73 m2) or severe (10–29 ml−1 min−1 per 1.73 m2) renal impairment received weekly injections of PEG‐IFN alfa‐2b (1.0 µg kg−1) for 4 weeks. Safety assessments were made before each injection and blood samples were taken up to 168 h after the final dose.

Results

Renal insufficiency increased PEG‐IFN alfa‐2b exposure. Area under the curve for 0–τ (dosing interval of 168 h), AUCτ, was increased 30% and 120% in patients with moderate or severe renal insufficiency, respectively. Mean maximum serum concentration was almost doubled in patients with severe insufficiency [1305.8 pg ml−1; 95% confidence interval (CI) 825, 1786] compared with subjects with normal renal function (731.4 pg ml−1; 95% CI 407, 1056), whereas the apparent volume of distribution was reduced (0.80 l kg−1vs. 1.28 l kg−1, respectively). Elimination half‐life was extended in patients with moderate and severe renal insufficiency (65.6 h and 64.9 h, respectively) compared with subjects with normal renal function (51.5 h). Significant differences were observed in the AUC and Cmax values of patients with severe renal dysfunction, compared with those who had normal renal function (P < 0.05; Kruskal–Wallis test). PEG‐IFN alfa‐2b was well tolerated and adverse events were similar in both treatment groups.

Conclusions

Exposure to PEG‐IFN alfa‐2b is increased in patients with renal insufficiency, suggesting that doses of the drug should be reduced by 50% in patients with severe renal insufficiency and by 25% in those with moderate insufficiency.